{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Safety summaries will include tabulations in the form of tables. The frequency of treatment-emergent AE's will be summarized. Additional AE summaries will include AE frequency by AE severity and relationship to the study drug. AE's requiring discontinuation of the study drug will be summarized separately, both overall and by AE severity and by relationship to the study drug. Clinically significant abnormal laboratory values will be summarized over study visits.","groups":[{"description":"Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRituximab: Given IV","id":"OG000","title":"Treatment (Ixazomib Citrate, Rituximab)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"AE data was intended to be assessed and reported as a single combined group for this study.","reportingStatus":"POSTED","timeFrame":"Up to 30 days after administration of the last dose of ixazomib citrate (Up to 6 years and 7 months).","title":"Incidence of Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}